When discussing the impact the United States’ new administration may have on pharmaceutical companies, GlaxoSmithKline’s Andrew Witty may have said it best: “I’ve had 30 years in this industry, and there’s never been a dull year. And there’s never been a year where it hasn’t felt challenging and interesting. And I suspect the next 30 years won’t be any different. But the reality is the industry does something quite amazing for people around the world. And as long as we keep doing that, it will be a very vibrant industry.”
There are various perspectives from which to look at the life sciences industry, and many ideas about how to help companies move forward. While the paths chosen may differ, everyone can all agree that more safe, life-saving medicines should be made available to patients, and that medication should be more affordable.
To explore several key issues and perspectives from industry executives that have the potential to significantly impact life sciences companies in 2017 and beyond, download The State of the Life Sciences Industry, our new guide.